Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Mallinckrodt
Farmers Insurance
Harvard Business School
Chubb
McKinsey
Fuji
AstraZeneca
Cipla
Julphar

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,334,270

« Back to Dashboard

Summary for Patent: 8,334,270
Title:Nucleoside phosphoramidate prodrugs
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: ##STR00001## Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Inventor(s): Sofia; Michael Joseph (Doylestown, PA), Du; Jinfa (New Hope, PA), Wang; Peiyuan (Glen Rock, NJ), Nagarathnam; Dhanapalan (Bethany, CT)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/099,671
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,334,270

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Sign Up
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Sign Up
Gilead Sciences Inc SOVALDI sofosbuvir TABLET;ORAL 204671-001 Dec 6, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF HEPATITIS C ➤ Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR ➤ Sign Up
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,334,270

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,906,880 Nucleoside phosphoramidate prodrugs ➤ Sign Up
7,964,580 Nucleoside phosphoramidate prodrugs ➤ Sign Up
9,085,573 Nucleoside phosphoramidate prodrugs ➤ Sign Up
8,580,765 Nucleoside phosphoramidate prodrugs ➤ Sign Up
8,735,372 Nucleoside phosphoramidate prodrugs ➤ Sign Up
9,585,906 Nucleoside phosphoramidate prodrugs ➤ Sign Up
8,957,046 Nucleoside phosphoramidate prodrugs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,334,270

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I357332 ➤ Sign Up
Taiwan 200904453 ➤ Sign Up
Slovenia 2203462 ➤ Sign Up
Singapore 2014011704 ➤ Sign Up
Singapore 179445 ➤ Sign Up
Russian Federation 2012152811 ➤ Sign Up
Russian Federation 2478104 ➤ Sign Up
Russian Federation 2009139968 ➤ Sign Up
Portugal 2203462 ➤ Sign Up
Philippines 12014502771 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Deloitte
Accenture
Fuji
Farmers Insurance
Daiichi Sankyo
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot